Remepy raised $36 million in Series A financing to expand pharmaceutical partnerships and fund global Phase III development of Hybridopa for Parkinson's disease.
- Amount
- $36M
- Stage
- Series A
- Announced
- 12 August 2026
- Leads
- O.G. Venture Partners, M Ventures
- Other investors
- NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, IT-Farm Corp
- Use of funds
- Accelerate pharmaceutical co-development partnerships, expand Hybrid Drug pipeline and platform, and fund global Phase III of Hybridopa.
- Total raised
- $62M to date
- Checked
- Announced by the company